Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

By J. Mchutchison, G. Everson, S. Gordon, I. Jacobson, M. Sulkowski, R. Kauffman, L. Mcnair, J. Alam, A. Muir. New England Journal of Medicine, 2009

1,049 citations recorded by the source corpus.

Subfields: Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/1bda55bf8186abb9c086a38ca43daefc746c38ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Z. Younossi

Citations in the corpus

• Telaprevir for retreatment of HCV infection. (2011, background): “Patients with bridging fibrosis or cirrhosis‡ 54/64 (84) 47/55 (85) 4/30 (13)”
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection (2011, neutral): “3 or 4 23 (7) 26 (8) 36 (12) 1 (2) 8 (15) 6 (11) 24 (7) 34 (9) 42 (11)”
• Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection (2011, neutral): “Rash events of any severity† 40 (7) 14 (9) 10 (6) 9 (8) 7 (7)”
• Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. (2009, neutral): “disorder 10 ( 12 ) 16 (20) 20 (26) 20 (24) 0 0 0 0”